| Ytd | 22.75% | |
| 1y | 204.15% |
| Open | 32.27 | Prev Close | 31.85 | Low | 32.27 | High | 32.27 | Mkt Cap | 1.89B |
| Vol | 7.30K | Avg Vol | 867.52K | EPS | -2.18 | P/E | -14.61 | Forward P/E | -11.62 |
| Beta | 0.76 | Short Ratio | 10.11 | Inst. Own | 111.66% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-13 | 50-d Avg | 31.27 | 200-d Avg | 28.17 | 1yr Est | 51.97 |
TYRA News
Analysts change outlook on top Wall Street names. SNX, ORCL, EDU, ENS, SHOO, RH, have price target c
Top Wall Street analysts changed outlook on top names. See full list of rating changes on analyst ra
Wall Street analysts change outlook on top names, including upgrades/downgrades. Check our analyst r
-Collaboration aims to raise awareness of UTUC and the need for continued innovation for patients li
Top Wall Street analysts upgraded STUB, PGNY, AMT, and BAP stocks and raised their price targets. Se
Tyra Biosciences develops targeted therapies for cancer and rare diseases, leveraging proprietary te
Tyra Biosciences, Inc. (TYRA) Presents at Bank of America Global Healthcare Conference 2026 Transcri
- Advanced "dabogratinib 3x3" strategy to pursue 3 late-stage clinical studies in LG-UTUC, IR NMIBC
CARLSBAD, Calif., May 7, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stag
Shares of Tyra Biosciences, Inc. (NASDAQ: TYRA - Get Free Report) have been assigned an average reco
-Seasoned biopharmaceutical leader brings deep commercial and strategic expertise to support TYRA's
'Top Wall Street analysts changed outlook on top names. See all rating changes incl. upgrades, d
Tyra Biosciences, Inc. (NASDAQ: TYRA - Get Free Report) Director Gilla Kaplan sold 14,295 shares of
Boone Capital added 398,482 shares of TYRA in the fourth quarter. The quarter-end position value ros
- Launched "dabogratinib 3x3" strategy to pursue 3 late-stage clinical studies in LG-UTUC, IR NMIBC
CARLSBAD, Calif., Feb. 23, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-st
CARLSBAD, Calif., Feb. 19, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-st
AquaBounty Technologies (NASDAQ: AQB - Get Free Report) and Tyra Biosciences (NASDAQ: TYRA - Get Fre
Robert More reported the sale of 246,871 shares on Nov. 21 as part of a Rule 10b5-1 trading plan. Th
Shares of Tyra Biosciences, Inc. (NASDAQ: TYRA - Get Free Report) have been assigned an average reco
Tyra Biosciences, Inc. (NASDAQ: TYRA - Get Free Report) hit a new 52-week high during trading on Fri
CARLSBAD, Calif. , Dec. 1, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-st
CARLSBAD, Calif. , Nov. 12, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-s
- Dosed first patients with dabogratinib in BEACH301 and SURF302; interim results from both studies
Shares of Tyra Biosciences, Inc. (NASDAQ: TYRA - Get Free Report) have received an average rating of
During Monday's trading, 1214 companies set new 52-week lows.
During Thursday, 849 stocks hit new 52-week lows.